The FDA is considering a second COVID-19 booster dose of the mRNA COVID-19 vaccines; use of the unproven COVID-19 therapies hydroxychloroquine and ivermectin has been significantly greater in the highest vs lowest Republican vote share counties; infertility treatments associated with vascular and pregnancy-related complications.
The Wall Street Journal reported that the FDA is “very carefully” considering whether a second COVID-19 booster dose of the mRNA COVID-19 vaccines would be warranted this Fall. Potentially coinciding with the typical administration of annual flu shots, FDA officials noted that the decision will be based on emerging data regarding the pandemic, safety and efficacy of booster vaccines, and the presence of variants in the United States and overseas. Currently, second booster doses are approved in Sweden for those over the age of 80 and in Israel for certain citizens, which may be expanded to all adults.
A study published recently in JAMA Internal Medicine showed that use of the unproven COVID-19 therapies hydroxychloroquine and ivermectin was significantly greater in the most populated Republican counties vs least populated. According to the The Hill, prescribing volume from June through December 2020 for hydroxychloroquine was 146% higher in the highest vs lowest Republican vote share counties than what it had been the previous year, with the volume of ivermectin prescriptions indicated to be 964% higher during this time as well.
Findings of a study published today in the Journal of the American Heart Association showed that women who used assisted reproductive technology to get pregnant may be at increased risk for vascular and pregnancy-related complications, particularly those aged 35 and older. Reported by CNN, analyses of 106,248 deliveries in which the baby was conceived with assisted reproductive technology compared with more than 34 million births conceived without such aid indicated that those who used the infertility treatments were at 2.5 times greater risk of acute kidney failure and 65% more likely to have an irregular heartbeat. Women who used the treatments were noted to have had more preexisting health conditions, such as high blood pressure and diabetes, as well as greater incidence of obesity when starting treatment.
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More
Cardiovascular Magnetic Resonance Highlights Sex-Specific Characteristics in Aortic Stenosis
February 19th 2025This multicenter study sheds more light on sex-based differences in aortic stenosis (AS) and argues the benefits of using cardiovascular magnetic resonance (CMR) to assess sex-based risks in AS.
Read More